Michael Schmertzler sold 20,000 PTC Therapeutics shares across three transactions dated 2026-09-09 and 2026-09-10, at prices ranging from $67.34 to $68.67 per share. He owned 1,316,594 shares afterward. The post-sale holding shows the reported ownership position investors can assess.
Key Highlights
- The PTC Therapeutics shares sold for between $67.34 and $68.67 per share.
- The transactions occurred on 9 September 2026 and 10 September 2026, all using code S.
- Michael Schmertzler owned 1,316,594 PTC Therapeutics shares after the transactions.
PTC Therapeutics, Inc. (NASDAQ: PTCT) saw Michael Schmertzler sell 20,000 shares in separate transactions. Michael Schmertzler was the seller named in the transaction record.
Three Transactions Cover $67.34 to $68.67 Per Share
Three separate transactions made up the reported activity. The prices ranged from $67.34 to $68.67 per share. The transactions were dated 9 September 2026 and 10 September 2026. Schmertzler owned 1,316,594 shares after the transactions.
FAQs
Q: What did Michael Schmertzler sell in PTC Therapeutics?
A: According to the filing, Michael Schmertzler sold 20,000 shares of PTC Therapeutics in three separate transactions. The sales took place between 9 September 2026 and 10 September 2026.
Q: What price range covered the PTC Therapeutics insider sales?
A: The PTC Therapeutics insider transactions were priced between $67.34 and $68.67 per share. All three reported transactions carried transaction code S and occurred on 9 September 2026 and 10 September 2026.
Q: How many PTC Therapeutics shares did Michael Schmertzler retain?
A: Following the reported transactions, Michael Schmertzler owned 1,316,594 shares of PTC Therapeutics. The filing identifies this as his ownership after the sales.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.